List of Figures
Figure 1: Pharmaceutical Supply Chain in the US, Number of Drug Callbacks, 2006–2011
Figure 2: Pharmaceutical Supply Chain in the US, Forecast Cold-chain Spending for Pharmaceuticals, $bn, 2011–2016
Figure 3: Pharmaceutical Supply Chain in the US, Evolution of Supply Chain Management, 2011
Figure 4: Pharmaceutical Supply Chain in the US, Implementation of Lean Supply Chain Management, 2011
Figure 5: Pharmaceutical Supply Chain in the US, Key Uncertainties Faced by Manufacturers, 2012
Figure 6: Pharmaceutical Supply Chain in the US, Number of Drug Callbacks, 2006–2011
Figure 7: Pharmaceutical Supply Chain in the US, Impact of Vioxx Withdrawal on Merck’s Share Prices, April 2003–October 2006
Figure 8: Pharmaceutical Supply Chain in the US, Risk Management Benefits, 2012
Figure 9: Pharmaceutical Supply Chain in the US, Risk Evaluation Procedure, 2012
Figure 10: Pharmaceutical Supply Chain in the US, Working of Radio Frequency Identification Technology, 2012
Figure 11: Pharmaceutical Supply Chain in the US, Structure of a Traditional Distribution Channel, 2012
Figure 12: Pharmaceutical Supply Chain in the US, Structure of a Limited Distribution Channel, 2012
Figure 13: Pharmaceutical Supply Chain in the US, Structure of a Direct-to-pharmacy Distribution Channel, 2011
Figure 14: Pharmaceutical Supply Chain in the US, Cold-chain Storage Forecast, $bn, 2011–2016
Figure 15: Pharmaceutical Supply Chain in the US, Counterfeit Drugs Identified, 2011
Figure 16: Pharmaceutical Supply Chain in the US, Wholesale Distributor Involved in Diversion Schemes, 2011
Figure 17: Pharmaceutical Supply Chain in the US, Pharmacies and Pharmacist Involved in Drug Diversion of Samples, 2011
Figure 18: Pharmaceutical Supply Chain in the US, Types of Trades Associated with Suspected Counterfeits, (%), 2011
Figure 19: Pharmaceutical Supply Chain in the US, Counterfeit Avastin Case Study, 2012
Figure 20: Pharmaceutical Supply Chain in the US, E-pedigree in a Pharmaceutical Supply Chain, 2012
Figure 21: Pharmaceutical Supply Chain in the US, Paper-based Pedigree in a Pharmaceutical Supply Chain, 2011
Figure 22: Pharmaceutical Supply Chain in the US, California E-pedigree Implementation Model, The US, 2012
Figure 23: Pharmaceutical Supply Chain in the US, Classification of Anti-counterfeit Technologies, 2012
Figure 24: Pharmaceutical Supply Chain in the US, Platform for Protecting Pharmaceutical Value Chain, 2012
Figure 25: Pharmaceutical Supply Chain in the US, Company Overview, Reed-Lane Inc, 2012
Figure 26: Pharmaceutical Supply Chain in the US, Company Overview, Cortegra Group Inc, 2012
Figure 27: Pharmaceutical Supply Chain in the US, Company Overview, NanoInk Inc, 2012
Figure 28: Pharmaceutical Supply Chain in the US, Company Overview, TraceLink, 2012
Figure 29: Pharmaceutical Supply Chain in the US, Company Overview, Axway, 2012
Figure 30: Pharmaceutical Supply Chain in the US, Company Overview, Innovatum Inc, 2012
Figure 31: Pharmaceutical Supply Chain in the US, Company Overview, Vetter Pharma International GmbH, 2012
Figure 32: Pharmaceutical Supply Chain in the US, Market Share of Wholesalers, (%), 2011
Figure 33: Pharmaceutical Supply Chain in the US, Company Profile, McKesson, 2011
Figure 34: Pharmaceutical Supply Chain in the US, Company Profile, AmerisourceBergen, 2011
Figure 35: Pharmaceutical Supply Chain in the US, Company Profile, Cardinal Health Inc, 2011
Figure 36: Pharmaceutical Supply Chain in the US, Market Share of Different Prescription-dispensing Channels, (%), 2011
Figure 37: Pharmaceutical Supply Chain in the US, Market Share of Top Three Chain Drug Stores, 2012